Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases
Alectinib for treatment of ALK-positive non-small-cell lung cancer
Alectinib for ALK-positive non-small-cell lung cancer
Alect2 amyloidosis: primum non nocere (first, do no harm)
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
Alectinib for advanced ALK-positive non-small-cell lung cancer
Alefacept in corticosteroid refractory graft versus host disease: Early results indicate promising activity
Alefacept Promotes Immunosuppression-Free Renal Allograft Survival in Nonhuman Primates via Depletion of Recipient Memory T Cells
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients
Alefacept for the treatment of psoriasis and other dermatologic diseases
Alefacept Therapy for Nephrogenic Systemic Fibrosis: A Case Series
Alefacept treatment for refractory chronic extensive GVHD
Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study
Alefacept: where it stands today
Alefacept for Psoriasis
Alefacept Combined With Tacrolimus, Mycophenolate Mofetil and Steroids in De Novo Kidney Transplantation: A Randomized Controlled Trial
Aleglitazar, a dual PPAR alpha and PPAR gamma agonist for the potential oral treatment of type 2 diabetes mellitus
Aleglitazar, a Balanced Dual PPAR alpha and -gamma Agonist, Protects the Heart Against Ischemia-Reperfusion Injury
Aleglitazar, a balanced PPAR alpha/gamma agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin
Aleglitazar, a dual peroxisome proliferator-activated receptor- and - agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia
阿乐画故宫之南十三排
A类颗粒流化床特性的DEM-CFD模拟
A类算子的谱性质
阿雷斯油田注水防膨保护剂室内实验研究及现场应用
A类群人格障碍与精神病
阿雷地平对轻中度原发性高血压病患者动态血压和动态动脉僵硬度指数的影响研究
阿雷斯库姆下侏罗统有机质成熟史模拟研究
阿雷地平肠溶胶囊对1、2级原发性高血压患者动态血压的影响
阿累尼乌斯方程探讨
A类算子n次根的代数扩张是次标量算子
A类CLE多肽调节拟南芥根尖韧皮部的发育
A类泡沫灭火系统应用技术研究
A类生产函数和B类生产函数是唯一的技术不变的理论生产函数
A类火灾试验用燃烧物标准样品研制
A类泡沫灭火剂的发展与瞻望
A类泡沫灭火剂的润湿性能研究
阿雷地平的合成
A类在《中国图书馆分类法》第五版中的列类研究
A类清道夫受体在肥胖相关性高血压中的作用及其机制研究
A类清道夫受体介导的巨噬细胞功能改变在炎症性心肌病中的作用的研究
Aleiodes Wesmael (Hymenoptera, Braconidae, Rogadinae) species described by Brethes: taxonomic clarification
A类Ⅰ型清道夫受体调节小鼠腹腔巨噬细胞抗肺炎克雷伯菌和铜绿假单胞菌感染
A类砌体房屋抗震性能对比及试算分析
阿类型面向对象语言及其动态类型检查
A类清道夫受体参与动脉粥样硬化形成的机制
A类清道夫受体N端第1~27位氨基酸胞浆结构域缺失对功能的影响
A类G蛋白偶联受体:结构、功能、计算机辅助药物设计及分子动力学模拟
Alejandro Flores Martinez (March 2 1962-April 12 2011) Biologist, has works published
阿勒锦岛岸坡非饱和土体固结试验研究
Aleksander Talerman, MD, Ph.D., FRC Path. Obituary
Aleksander Luria and diaschisis
Aleksandrov-Bakelman-Pucci Type Estimates for Integro-Differential Equations
Aleksandr Mikhailovich Butlerov and chemical structure: Tribute to a scientist and to a 150-year old concept
Aleksandrov-Clark Theory for Drury-Arveson Space
Aleksandrov-Bakelman-Pucci maximum principles for a class of uniformly elliptic and parabolic integro-PDE
Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia
Alemtuzumab induction therapy in highly sensitized kidney transplant recipients
Alemtuzumab Induction in Non-Hepatitis C Positive Liver Transplant Recipients
Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center
Alemtuzumab (CAMPATH-1H) for the Treatment of Acute Rejection in Kidney Transplant Recipients: Long-Term Follow-Up
Alemtuzumab induction in renal transplantation: A meta-analysis and systemic review
Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks (review)
Alemtuzumab induction in pediatric kidney transplantation
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety
Alemtuzumab and chronic plaque psoriasis
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis
Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients
Alemtuzumab The advantages and challenges of a novel therapy in MS
Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis
Alemtuzumab Treatment of Multiple Sclerosis
Alemtuzumab Therapy for Multiple Sclerosis
Alemtuzumab Induction in Lung Transplantation: Time to Move On?
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients
Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus
Alemtuzumab and Treatment of Chronic Lymphocytic Leukemia and Its Immune-Related Disorders: One Player on Two Tables
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series
Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management
Alemtuzumab induction therapy in kidney transplantation Reply